Up 42% since January: Why Merck is defeating the patent cliff
In short
Merck has seen its shares advance significantly since the beginning of the year amid sustained investor demand. The pharmaceutical company has managed to rise 42% since January, outperforming broader industry headwinds. Market confidence reflects an improved operational outlook as the firm actively works through its impending patent cliff.
Key points
- Merck shares have surged 42% since January following renewed optimism over exclusivity ri…: Merck shares have surged 42% since January following renewed optimism over exclusivity risks.
- The drugmaker continues to demonstrate measurable progress in navigating major patent cli…: The drugmaker continues to demonstrate measurable progress in navigating major patent cliffs.
- Consistent commercial execution has sustained the company's strong upward trajectory this…: Consistent commercial execution has sustained the company's strong upward trajectory this year.